X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs ALKEM LABORATORIES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA ALKEM LABORATORIES ALEMBIC PHARMA/
ALKEM LABORATORIES
 
P/E (TTM) x 28.2 - - View Chart
P/BV x 6.4 7.6 84.4% View Chart
Dividend Yield % 0.7 0.6 128.8%  

Financials

 ALEMBIC PHARMA   ALKEM LABORATORIES
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
ALKEM LABORATORIES
Mar-16
ALEMBIC PHARMA/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs7921,589 49.8%   
Low Rs4431,232 36.0%   
Sales per share (Unadj.) Rs167.0417.5 40.0%  
Earnings per share (Unadj.) Rs38.256.3 67.8%  
Cash flow per share (Unadj.) Rs42.064.7 64.9%  
Dividends per share (Unadj.) Rs4.0012.70 31.5%  
Dividend yield (eoy) %0.60.9 72.0%  
Book value per share (Unadj.) Rs84.9292.9 29.0%  
Shares outstanding (eoy) m188.52119.57 157.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.73.4 109.4%   
Avg P/E ratio x16.225.1 64.6%  
P/CF ratio (eoy) x14.721.8 67.4%  
Price / Book Value ratio x7.34.8 151.0%  
Dividend payout %10.522.6 46.5%   
Avg Mkt Cap Rs m116,383168,653 69.0%   
No. of employees `000NANA-   
Total wages/salary Rs m4,2149,171 45.9%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m31,48749,915 63.1%  
Other income Rs m551,645 3.3%   
Total revenues Rs m31,54251,561 61.2%   
Gross profit Rs m10,0608,482 118.6%  
Depreciation Rs m7221,006 71.8%   
Interest Rs m37671 5.5%   
Profit before tax Rs m9,3568,451 110.7%   
Minority Interest Rs m0-114 0.0%   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,1601,606 134.5%   
Profit after tax Rs m7,1946,731 106.9%  
Gross profit margin %31.917.0 188.0%  
Effective tax rate %23.119.0 121.5%   
Net profit margin %22.813.5 169.4%  
BALANCE SHEET DATA
Current assets Rs m15,06627,062 55.7%   
Current liabilities Rs m7,67415,324 50.1%   
Net working cap to sales %23.523.5 99.8%  
Current ratio x2.01.8 111.2%  
Inventory Days Days6767 100.7%  
Debtors Days Days4141 98.4%  
Net fixed assets Rs m8,23712,610 65.3%   
Share capital Rs m377239 157.7%   
"Free" reserves Rs m15,41634,490 44.7%   
Net worth Rs m16,00535,027 45.7%   
Long term debt Rs m01,212 0.0%   
Total assets Rs m24,59454,387 45.2%  
Interest coverage x255.213.6 1,876.5%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.30.9 139.5%   
Return on assets %29.413.6 216.0%  
Return on equity %44.919.2 233.9%  
Return on capital %58.724.9 236.1%  
Exports to sales %55.712.9 430.6%   
Imports to sales %10.43.1 337.9%   
Exports (fob) Rs m17,5516,461 271.6%   
Imports (cif) Rs m3,2831,540 213.1%   
Fx inflow Rs m17,8116,563 271.4%   
Fx outflow Rs m5,3183,012 176.6%   
Net fx Rs m12,4933,552 351.7%   
CASH FLOW
From Operations Rs m9,3047,259 128.2%  
From Investments Rs m-3,1051,864 -166.5%  
From Financial Activity Rs m-1,959-9,273 21.1%  
Net Cashflow Rs m4,240-150 -2,826.7%  

Share Holding

Indian Promoters % 74.1 66.9 110.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 33.1 8.8%  
FIIs % 9.1 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 0.0 -  
Shareholders   49,328 68,381 72.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   ELDER PHARMA  FDC LTD.  SUN PHARMA  DISHMAN PHARMA  TTK HEALTHCARE  

Compare ALEMBIC PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Surges 300 Points; Tata Steel Up 3.5%(01:30 pm)

After opening the day in green, share markets in India have continued the momentum and are presently trading near all-time high levels. Sectoral indices are trading on a positive note.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Jan 23, 2018 03:34 PM

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 5-YR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS